Canopus BioPharma Incorporated
Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. It also provides antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceutricals. The company was founded in 1996 as Canopus Corporation and chan… Read more
Market Cap & Net Worth: Canopus BioPharma Incorporated (CBIA)
Canopus BioPharma Incorporated (PINK:CBIA) has a market capitalization of $278.77K ($278.77K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #51410 globally and #16092 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Canopus BioPharma Incorporated's stock price $0.00 by its total outstanding shares 2787729920 (2.79 Billion).
Canopus BioPharma Incorporated Market Cap History: 2015 to 2025
Canopus BioPharma Incorporated's market capitalization history from 2015 to 2025. Data shows change from $501.79 Million to $278.77K (-55.54% CAGR).
Canopus BioPharma Incorporated Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Canopus BioPharma Incorporated's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CBIA by Market Capitalization
Companies near Canopus BioPharma Incorporated in the global market cap rankings as of March 19, 2026.
Key companies related to Canopus BioPharma Incorporated by market ranking:
- Applovin Corp (NASDAQ:APP): Ranked #180 globally with a market cap of $107.18 Billion USD.
- Publicis Groupe S.A (OTCQX:PGPEF): Ranked #1024 globally with a market cap of $19.01 Billion USD.
- Omnicom Group Inc (NYSE:OMC): Ranked #1264 globally with a market cap of $14.57 Billion USD.
- Trade Desk Inc (NASDAQ:TTD): Ranked #1669 globally with a market cap of $10.12 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Applovin Corp | NASDAQ:APP | $107.18 Billion | $442.57 |
| #1024 | Publicis Groupe S.A | OTCQX:PGPEF | $19.01 Billion | $87.10 |
| #1264 | Omnicom Group Inc | NYSE:OMC | $14.57 Billion | $76.08 |
| #1669 | Trade Desk Inc | NASDAQ:TTD | $10.12 Billion | $23.55 |
Canopus BioPharma Incorporated Historical Marketcap From 2015 to 2025
Between 2015 and today, Canopus BioPharma Incorporated's market cap moved from $501.79 Million to $ 278.77K, with a yearly change of -55.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $278.77K | 0.00% |
| 2024 | $278.77K | -66.67% |
| 2023 | $836.32K | -99.25% |
| 2022 | $111.51 Million | -69.23% |
| 2021 | $362.40 Million | +333.33% |
| 2020 | $83.63 Million | -75.21% |
| 2019 | $337.32 Million | +3.86% |
| 2018 | $324.77 Million | -47.05% |
| 2017 | $613.30 Million | +100.00% |
| 2016 | $306.65 Million | -38.89% |
| 2015 | $501.79 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Canopus BioPharma Incorporated was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $278.77K USD |
| MoneyControl | $278.77K USD |
| MarketWatch | $278.77K USD |
| marketcap.company | $278.77K USD |
| Reuters | $278.77K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.